CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose
PR Newswire —
SEATTLE, March 10, 2026 /PRNewswire/ -- CounterX Therapeutics, a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the execution of an exclusive licensing agreement with the University of...